News and Events
| Thursday, 16 December 2010 00:00 |
BACKGROUND:Apoptosis is an early event involved in cardiomyopathy associated with diabetes mellitus. Toll-like receptor (TLR) signaling triggers cell apoptosis through multiple mechanisms. Up-regulation of TLR4 expression has been shown in diabetic mice. This study aimed to delineate the role of TLR4 in myocardial apoptosis, and to block this process through gene silencing of TLR4 in the myocardia of diabetic mice. METHODS:Diabetes was induced in C57/BL6 mice by the injection of streptozotocin. Diabetic mice were treated with 50 μg of TLR4 siRNA or scrambled siRNA as control. Myocardial apoptosis was determined by TUNEL assay. RESULTS:After 7 days of hyperglycemia, the level of TLR4 mRNA in myocardial tissue was significantly elevated. Treatment of TLR4 siRNA knocked down gene expression as well as diminished its elevation in diabetic mice. Apoptosis was evident in cardiac tissues of diabetic mice as detected by a TUNEL assay. In contrast, treatment with TLR4 siRNA minimized apoptosis in myocardial tissues. Mechanistically, caspase-3 activation was significantly inhibited in mice that were treated with TLR4 siRNA, but not in mice treated with control siRNA. Additionally, gene silencing of TLR4 resulted in suppression of apoptotic cascades, such as Fas and caspase-3 gene expression. TLR4 deficiency resulted in inhibition of reactive oxygen species (ROS) production and NADPH oxidase activity, suggesting suppression of hyperglycemia-induced apoptosis by TLR4 is associated with attenuation of oxidative stress to the cardiomyocytes. CONCLUSIONS:In summary, we present novel evidence that TLR4 plays a critical role in cardiac apoptosis. This is the first demonstration of the prevention of cardiac apoptosis in diabetic mice through silencing of the TLR4 gene. CEO, Dr. Vlad Bogin collaborates on a scientific publication describing new gene responsible for heart damage in diabetics. For more detailed information see abstract of the article. |
News and messages from CEO,
Dr Vladimir Bogin
12.04.2012 |
Cromos™ Pharma has announced today an addition of a new service - registration of medicinal products in the Russian Federation. [...] |
19.03.2012 |
Meet us at ASCO Annual Meeting in Chicago, IL, USA on 1-5 June 2012. [...] |
12.01.2012 |
Cromos Pharma has participated in the conference on clinical trials in emerging markets in Tel-Aviv, Israel on 11 January 2012. [...] |
05.01.2012 |
Meet Cromos Pharma's CEO, Dr. Vladimir Bogin at the 30th JP Morgan Healthcare Conference in San Francisco, CA on 9-12 January 2012. [...] |
14.12.2011 |
Cromos Pharma published a white paper with review of Russian clinical trials market in 2011. [...] |


